Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Role of Adjuvant Radiation Therapy in Pancreas Cancer

October 10th 2017

Adjuvant Therapy Recommendations in Pancreas Cancer

October 10th 2017

Pancreas Cancer: Incorporating Nanoliposomal Irinotecan

October 10th 2017

Palliative Care Recommendations in Pancreas Cancer

October 10th 2017

Modifying Chemotherapy Regimens in Pancreas Cancer

October 10th 2017

Sequential Therapy for Metastatic Pancreas Cancer

October 10th 2017

Precision Medicine for Pancreatic Cancer

October 10th 2017

Biological Breakthroughs in Pancreas Cancer

October 10th 2017

Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer

October 6th 2017

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

Pancreatic Cancer Advocacy Group Leads the Charge for Innovation

October 5th 2017

In its fight against pancreatic cancer, the Pancreatic Cancer Action Network aims to improve current survival and double survival by 2020.

Dr. Welling on the Efficacy of Nivolumab in HCC

October 4th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Novel Targets and Biomarkers Emerge in Pancreatic Cancer

October 2nd 2017

There is an urgent need for new approaches, particularly since pancreatic cancer is expected to become the second leading cause of cancer-related mortality by 2030.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

Expert Discusses Ongoing Advances With Immunotherapy in CRC

September 28th 2017

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

PEGPH20 Could Alter Frontline Treatment in Pancreatic Cancer

September 27th 2017

Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field.

FDA Accepts Lenvatinib Application for Advanced HCC

September 27th 2017

The FDA has accepted a supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma.

Dr. Alberts Discusses Updates in Liver Cancer

September 26th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Grothey Highlights Biomarker Research in CRC

September 26th 2017

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Therapies in Development to Improve Outcomes in BRAF-Mutated CRC

September 26th 2017

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Therapeutic Advancements Changing Liver Cancer Paradigm

September 26th 2017

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.